NL-OMON27591招募中不适用
Dendritic Cells loaded with allogeneic tumor lysate (MesoPher) in combination with a CD40 agonist (Mitazalimab) for metastatic pancreatic disease
Department of Pulmonary Medicine, Erasmus MC0 个研究点目标入组 18 人开始时间: 待定最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 18
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Metastatic pancreatic cancer as defined by the presence of radiologically suspect metastatic lesions.
- •Progressive disease on first-line FOLFIRINOX or modified FOLFIRINOX for metastatic pancreatic cancer. No more than 1 line of chemotherapy for metastatic disease is allowed. Prior FOLFIRINOX for locally advanced disease if given within 1 year before screening can be counted as first-line treatment. Any FOLFIRINOX given in the curative intent setting if more than a year before screening will not be considered first line therapy•
- •An accessible metastatic lesion for histological tissue collection.
- •Patients must be at least 18 years old and must be able to give written informed consent.
- •WHO performance status 0-1.
- •Patients must have normal organ function and adequate bone marrow reserve: absolute neutrophil count > 1.0 x 109/l, platelet count > 100 x 109/l, and Hb > 6.0 mmol/l (as determined during screening). Transfusion in the 2 weeks preceding screening is not allowed.
- •Laboratory tests: ASAT/ALAT <5xULN (upper limit of normal), bilirubine <1.5xULN, Creatinine value <1.5xULN, Lactate dehydrogenase value < ULN and albumin value > LLN (lower limit of normal).
- •Women of childbearing potential must have a negative serum pregnancy test at screening and a negative urine pregnancy test just prior to the first study drug administration on Day 1, and must be willing to use an effective contraceptive method (intrauterine devices, hormonal contraceptives, contraceptive pill, implants, transdermal patches, hormonal vaginal devices, infusions with prolonged release) or true abstinence (when this is in line with the preferred and usual lifestyle)* during the study and for at least 12 months after the last study drug administration. *True abstinence is acceptable when this is in line with the preferred and usual lifestyle of the subject. Periodic abstinence (such as calendar, ovulation, symptothermal, postovulation methods) and withdrawal are not acceptable methods of contraception.
- •Men must be willing to use an effective contraceptive method (e.g. condom, vasectomy) during the study and for at least 12 months after the last study drug administration.
- •Ability to return to the hospital for adequate follow-up as required by this protocol.
- •Written informed consent according to ICH-GCP.
排除标准
- •Medical or psychological impediment to probable compliance with the protocol.
- •Abdominal ascites.
- •Current or previous use of a CD40 antibody and/or anti-tumor vaccinations. • Current use of steroids (or other immunosuppressive agents). Patients must have had 6 weeks of discontinuation and must stop any such treatment during the time of the study. Prophylactic usage of dexamethasone during chemotherapy is excluded from this 6 weeks interval.
- •Prior malignancy except adequately treated basal cell or squamous cell skin cancer, superficial or in-situ cancer of the bladder or other cancer for which the patient has undergone curative intent treatment and has been disease-free for two years.
- •Serious concomitant disease, or active infections.
- •Serious intercurrent chronic or acute illness such as pulmonary disease (asthma or COPD), cardiac disease (NYHA class III or IV), hepatic disease or other illness considered by the study coordinator to constitute an unwarranted high risk for the investigational treatment.
- •Known allergy to shell fish (may contain keyhole limpet hemocyanin (KLH)). • Pregnant or lactating women.
- •Inadequate vein access to perform leukapheresis.
- •Concomitant participation in another clinical intervention trial (except participation in a biobank study).
- •An organic brain syndrome or other significant psychiatric abnormality which would compromise the ability to give informed consent, and preclude participation in the full protocol and follow-up.
研究者
相似试验
已完成
不适用
Dendritic Cells loaded with allogeneic tumor lysate (MesoPher) in combination with a CD40 agonist (Mitazalimab) in metastatic pancreatic disease (REACtiVe-2 Trial)NL-OMON52234Erasmus MC, Universitair Medisch Centrum Rotterdam30
进行中（未招募）
1 期
Dendritic cell immunotherapy in patients with surgically resected pancreatic cancer who have received adjuvant standard of care treatment.(borderline) resectable pancreatic adenocarcinomaMedDRA version: 20.0Level: LLTClassification code 10033578Term: Pancreas carcinoma resectableSystem Organ Class: 100000004864EUCTR2018-003222-92-NLErasmus MC26
已完成
1 期
Dendritic cell immunotherapy for patients with resected pancreatic cancer<p>Pancreatic cancer, alvleesklierkanker, pancreascarcinoom</p>10015674NL-OMON28791Erasmus Medical Center10
进行中（未招募）
不适用
Vaccine with dendritic cells pulsed tumoral cell line or with autologue tumor in patients with kidney carcinoma - NDkidney carcinomaMedDRA version: 6.1Level: PTClassification code 10038415EUCTR2006-004751-38-ITOSPEDALE ONCOLOGICO DI BARI
撤回
2 期
Autologous Dendritic Cells Loaded with Allogenic Tumor Lysate for Surgically Resected Pancreatic Cancer Patients (REACtiVe trial).pancreatic cancerNL-OMON46414Erasmus MC, Universitair Medisch Centrum Rotterdam10